Badoux XC et al. Final analysis of a Phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Proc ASH 2011;Abstract 980.

James DF et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia (CLL): A multicenter study of the CLL research consortium. Proc ASH 2011;Abstract 291.

Egle A et al. A combination of fludarabine/rituximab with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II study, clinical and exploratory analyses of induction results. Proc ASH 2011;Abstract 292.

Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.

Dr Leonard is Richard T Silver Distinguished Professor of Hematology and Medical Oncology and Professor of Medicine at Weill Cornell Medical College in New York, New York.